Exploring the Potential Relationship between Gut Microbiome Metabolites and Idiopathic Pulmonary Fibrosis via Network Pharmacology Study
Fibrosis · 2024
DOI: 10.70322/fibrosis.2024.10009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fibrosis, 2024. Verfasst von Zhenwei Li und 6 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease with a poor prognosis. Previous research has revealed that the gut microbiota is associated with human health and immunity, and it interacts with the lung through the “gut-lung axis”. This study explores the potential relationship between Gut Microbiome Metabolites and Idiopathic pulmonary fibrosis via Network Pharmacology Study. The metabolites from gut microbiota were retrieved from the gutMGene database, and gene targets for these metabolites were obtained from previous studies. Gene targets of IPF were obtained from public databases (DisGeNET, OMIM). Subsequently, following the identification of shared targets, IL6 was determined as the core target through protein-protein interaction analysis. Then, a microbiota-metabolite-target-signaling pathway network (MMTS) was constructed using Cytoscape 3.10, and targets with low expression in the lungs and intestines were deleted. The MMTS network revealed that three short-chain fatty acids—acetate, butyrate, propionate, and a flavonoid compound called equol—are IL6-related metabolites. Then, we performed a molecular docking test (MDT) using CB-Dock2 to validate the affinity between core targets and metabolites. MDT confirmed that equol produced by the conversion of isoflavones from Lactobacillus paracasei JS1 was more stable in binding to IL6 than the other three short-chain fatty acids, thereby affecting multiple signaling pathways and influencing the progression of IPF. Finally, we validated this hypothesis through in vitro cell culture experiments, further confirming the effect of Equol.
Zitieren
APA
Li, Z., Zhu, Z., Wang, J., Zhang, M., Gan, Y., Yan, Y., & Wang, L. (2024). Exploring the Potential Relationship between Gut Microbiome Metabolites and Idiopathic Pulmonary Fibrosis via Network Pharmacology Study. Fibrosis. https://doi.org/10.70322/fibrosis.2024.10009
Vancouver
Li Z, Zhu Z, Wang J, Zhang M, Gan Y, Yan Y, et al. Exploring the Potential Relationship between Gut Microbiome Metabolites and Idiopathic Pulmonary Fibrosis via Network Pharmacology Study. Fibrosis. 2024. doi:10.70322/fibrosis.2024.10009
BibTeX
@article{Li2024,
author = {Li, Zhenwei and Zhu, Zhao and Wang, Jiawei and Zhang, Mengke and Gan, Yulong and Yan, Yinan and Wang, Lan},
title = {Exploring the Potential Relationship between Gut Microbiome Metabolites and Idiopathic Pulmonary Fibrosis via Network Pharmacology Study},
journal = {Fibrosis},
year = {2024},
doi = {10.70322/fibrosis.2024.10009}
}
EUVIMED